Controlled-Release GLP-1 Composition for Levodopa Dyskinesia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Long-term administration of levodopa in Parkinson's disease patients leads to levodopa-induced dyskinesia, a severe side effect characterized by abnormal involuntary movements, due to increased sensitivity to dopamine receptors, and existing treatments like GLP-1 receptor agonists face challenges in effectively crossing the blood-brain barrier and maintaining therapeutic efficacy.
Innovation Solution
A controlled-release formulation of exendin-4 or exenatide, combined with a biodegradable polymer and a coating layer containing basic amino acids, is designed to provide sustained delivery of the GLP-1 receptor agonist across the blood-brain barrier, reducing the side effects of levodopa and alleviating abnormal involuntary movements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long-term levodopa therapy is administered to treat Parkinson's disease, then motor symptoms are improved, but levodopa-induced dyskinesia and neurotoxicity occur
Solution Approach 1:
The patent introduces GLP-1 receptor agonists (exendin-4 or exenatide) as intermediary substances that modulate the dopaminergic system and reduce levodopa-induced dyskinesia. These agonists act as mediators between levodopa therapy and the development of dyskinesia, providing neuroprotection and reducing abnormal involuntary movements through GLP-1 receptor activation in the brain.
Solution Approach 2:
The patent employs a composite delivery system combining GLP-1 receptor agonist with biodegradable polymer (polylactide, polyglycolide, or poly(lactide-co-glycolide)) and basic amino acid coating (arginine, lysine, or histidine). This composite formulation enables controlled release and enhances blood-brain barrier penetration, allowing simultaneous achievement of therapeutic efficacy and dyskinesia reduction.
2Object-affected harmful factors
If GLP-1 receptor agonists are administered to reduce dyskinesia, then abnormal involuntary movements are reduced, but the drug cannot effectively cross the blood-brain barrier
Solution Approach 1:
Basic amino acids (arginine, lysine, or histidine) serve as intermediary substances that facilitate blood-brain barrier penetration. When coated on the polymer surface, these amino acids act as mediators that enable the GLP-1 receptor agonist to cross the blood-brain barrier effectively, overcoming the natural barrier to CNS delivery.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the drug delivery system by controlling polymer intrinsic viscosity (0.1 to 0.5 dL/g) and applying amino acid coatings. These parameter changes enhance the formulation's ability to cross the blood-brain barrier while maintaining controlled release characteristics.
3Duration of action of moving object
If a controlled-release formulation is used to maintain therapeutic levels, then drug efficacy is sustained, but the formulation complexity increases
Solution Approach 1:
The patent controls the release rate and therapeutic duration by adjusting polymer parameters, specifically intrinsic viscosity (0.1 to 0.5 dL/g) and molecular weight. By optimizing these parameters, the formulation achieves sustained release of the GLP-1 receptor agonist without requiring complex multi-component systems or sophisticated release mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively reduces the severity of levodopa-induced dyskinesia by normalizing dopamine turnover and improving motor symptoms, while preventing the onset or progression of dyskinesia when administered with levodopa.
Implementation Method 1
a biodegradable polymer is at least one selected from the group consisting of polylactide, polyglycolide and poly(lactide-co-glycolide)
Implementation Method 2
designed to provide sustained delivery of the GLP-1 receptor agonist across the blood-brain barrier
Data Source
Figure 1
Figure 2C~2B2
Figure 3A~4
AI summary
The present invention relates to a pharmaceutical composition for treatment or prevention of levodopa-induced dyskinesia. The GLP-1 receptor agonist or the controlled-release formulation thereof according to the present invention has effects of reducing serious side effects due to long-term use of levodopa when administered in combination with levodopa, and also effects of alleviating or improving abnormal involuntary movements (AIMs) caused by levodopa.